A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)
Trial details
- Registry ID
- NCT06568627
- Drugs studied
- EscharEx (EX-03)
TrialRedline tracks 4 clinical trials sponsored by MediWound Ltd: 3 Phase 3, 1 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)NCT06568627 | EscharEx (EX-03) | Recruiting | 2026-12Estimated |
| A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of CareNCT02278718 | NexoBrid, Standard of Care | Completed | 2021-04Actual |
| A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal BurnsNCT02148705 | Gel Vehicle, NexoBrid, Standard of Care (SOC) | Completed | 2018-06-12Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Controlled Study, Performed to Evaluate the Safety and Efficacy of EscharEx and Its Placebo (Gel Vehicle) Compared to Non-surgical Standard of Care in Participants With Venous Leg Ulcers (VLU)NCT06690177 | EscharEx (EX-03) | Not yet recruiting | 2028-11-04Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2022-12-28Day | NexoBridMediWound Ltd · MDWD | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA761192", "applicant_as_listed_by_fda": "MEDIWOUND, LTD", "brand_names": ["NEXOBRID"], "active_ingredients": ["ANACAULASE-BCDB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20221228", "matched_on": "drug name equals FDA brand name"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |
Names as written in the registry records.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Incidence (number of patients) of target wound related AEs throughout the trial Description: The endpoint will assess number of patients, in each arm, with reported local (target wound related) AEs Time frame: Throughout the study (week 2- week 15) Measure: Number of patients with Clinically significant changes in vital signs during the Daily Visits Period, Description: Number of patients with Clinically significant changes in vital signs Time frame: Weeks 2-3 (14 days) Measure: Number of patients with Clinically significant changes in clinical laboratory parameters Description: Number of patients with Clinically significant changes in clinical laboratory parameters Time frame: Weeks 2-3 (14 days) Measure: Time to complete wound closure Description: The outcome will assess time to reaching complete wound closure Time frame: Weeks 2-15 Measure: Incidence of complete wound closure Description: The outcome will assess number of patients reaching complete wound closure Time frame: 2-15 weeks. After: Measure: Incidence (number of patients) of systemic and local adverse events (AEs) throughout the trial Description: The endpoint will assess number of patients, in each arm, with reported systemic and local AEs Time frame: Throughout the study (week 2- week 17) Measure: Number of patients with Clinically significant changes in vital signs during the Daily Visits Period, Description: Number of patients with Clinically significant changes in vital signs Time frame: Weeks 2-3 (14 days) Measure: Number of patients with Clinically significant changes in clinical laboratory parameters Description: Number of patients with Clinically significant changes in clinical laboratory parameters Time frame: Weeks 2-3 (14 days) Measure: Time to complete wound closure Description: The outcome will assess time to reaching complete wound closure Time frame: Weeks 2-17 Measure: Incidence of complete wound closure Description: The outcome will assess number of patients reaching complete wound closure Time frame: 2-17 weeks.
Before: 30 Dec 2027. After: 4 Nov 2028.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Incidence of complete debridement, clinically (visually) assessed after each application Measure: Incidence of complete wound closure. After: Measure: Incidence of complete debridement, clinically (visually) assessed after each application Measure: Facilitation of wound closure, clinically assessed, as measured by time to complete wound closure.